Omada Health, Inc. is a virtual-first care platform that delivers between-visit care for chronic conditions. The company offers programs for cardiometabolic health, including prediabetes, weight management, type 1 and type 2 diabetes, hypertension, and high cholesterol, as well as musculoskeletal conditions. Its services combine human-led care teams with digital tools, including a mobile app, connected devices, and AI-driven personalization. Omada supports members on GLP-1 therapies and offers an Enhanced Care Track for long-term weight management. The company sells its programs to employers, health insurance companies, pharmacy benefit managers, and health systems, either directly or through channel partners. It partners with Physera Physical Therapy Group, PC to deliver clinical services for musculoskeletal care. Founded in 2012, the company focuses on evidence-based care and personalized support to help individuals make lasting health changes.

Summarised from the company's own disclosures, fiscal year ended Mar 2026

Industry Health Information Services Homepage omadahealth.com
Sector Healthcare IR page omadahealth.com
Tags
virtual care, chronic disease management, diabetes prevention, weight management, hypertension, cholesterol management, musculoskeletal care, glp-1 therapy support, health coaching, digital health, Omada for Prevention & Weight Health, Omada for Diabetes, Omada for Hypertension, Omada for Cholesterol, Omada GLP-1 Care Track, Omada for MSK, Physera Physical Therapy Group PC
Press page omadahealth.com/resource-center/tag/press-release

Metrics

Valuation  
Market cap $ 1.191B
Market cap (USD) $ 1.191B
P/E -54.90
PEG —
P/BV 4.36
P/S 4.58
P/OCF 65.27
P/FCF 70.37
Dividend yield —
Turnover / mcap —
Returns  
ROE -5.6%
ROI -167.2%
ROIC -117.5%
Profit margin -4.9%
Growth  
Revenue growing Yes
Profits growing Yes
Revenue up 3y Yes
Revenue up 5y —
Earnings growth 3y (net profit CAGR) —
Quality  
Profitable No
Margin expanding Yes
Buying back stock No
Diluting (TTM) Yes
Debt/Equity —
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 64
Quality score -25.0%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2025 FY 2024 FY 2023 FY 2022
Revenue 260.21M 169.8M 122.784M 89.185M
Net profit -12.778M -47.137M -67.511M -72.518M
Free cash flow 16.93M -38.042M -52.659M -71.701M

Figure FY 2025 FY 2024 FY 2023 FY 2022
Share price 15.78 — — —
P/FCF 54.46 — — —

Filed figures

Figure Dec 2022 Dec 2023 Dec 2024 Dec 2025
Balance sheet detail
Trade receivables (USD) — — 23.4M 34.6M
↳ YoY growth +47.7%
Lease liabilities (USD) — — 415,000 0.00
Cash and deposits (USD) 168M 116M 76.4M 222M
Intangible assets (USD) — — 4.26M 2.41M
Right-of-use assets (USD) — — 447,000 0.00
Cash flow detail
Operating cash flow (USD) — -49.7M -34.2M 18.3M
Purchases of property, plant and equipment (USD) — -416,000 -596,000 -1.32M
Change in receivables (cash effect) (USD) — -5.34M -8.81M -12.4M
Change in inventories (cash effect) (USD) — -74,000 318,000 -1.19M
Change in payables (cash effect) (USD) — -286,000 399,000 6.29M
Interest paid (cash effect) (USD) — -4.1M -3.85M -2.42M
Share-based compensation (USD) — 8.74M 9.42M 13M
Operating cash flow before change in receivables (USD) — -44.4M -25.4M 30.6M
Free cash flow (OCF - PPE - intangibles) (USD) — -50.2M -34.8M 16.9M
Income detail
Research and development expense (USD) — 33.7M 35.9M 40.7M
Total comprehensive income (USD) — -67.5M -47.1M -12.8M
Comprehensive income to owners (USD) — -67.5M -47.1M -12.8M
Provision for credit losses (USD) — 452,000 1.76M 1.19M
Credit cost ratio (credit losses / average receivables) (%) — — — 4.1%
Reported Mar 6, 2026 Mar 6, 2026 Mar 6, 2026 Mar 6, 2026

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

Omada Health Reports Third Quarter 2026 Results Bull 6 Bear 0 Results

•Quarterly Revenue of $91 million and All-Time High Total Members of 1.1 million

•Revenue Grew 34% and Total Members Increased 36% Year over Year

•Raises Full Year 2026 Financial Outlook

SAN FRANCISCO - November 5, 2026 - Omada Health, Inc. (Nasdaq: OMDA), the virtual between-visit healthcare provider, today reported financial results for the third quarter ended September 30, 2026.

Financial Highlights

•Revenue of $91 million, compared with total revenue of $68 million in Q3 2025

•Gross margin of 76% in the third quarter, up from 66% in Q3 2025

•Non-GAAP gross margin of 78% in the third quarter, up from 68% in Q3 2025

•Net income of $7 million in the third quarter, compared with a net loss of $3 million in Q3 2025

•Adjusted EBITDA of $12 million in the third quarter, compared with Adjusted EBITDA of $2 million in Q3 2025

•Trailing 12-month revenue per Total Member grew approximately 5% year over year to $294

•Cash and cash equivalents of $243 million

Please see the non-GAAP Financial Measures section below and reconciliations of GAAP to non-GAAP measures at the end of this press release.

October 20, 2026

Omada Health to Present Peer-Reviewed Research on Improving Weight Loss and Body Composition During GLP-1 Treatment at World Obesity and Weight Management Congress

The oral presentation will share results from a 12-week comparative study showing that Omada GLP-1 Care Track members, on average, lost more weight and saw greater improvements in body composition than controls

SAN FRANCISCO – October 20, 2026 – Omada Health (Nasdaq: OMDA), the virtual between-visit healthcare provider, announced it will present research at the World Obesity and Weight Management Congress (WOC 2026) in Boston showing that members of its GLP-1 Care Track lost more weight and experienced greater improvements in body composition than GLP-1 users receiving usual care. The findings were recently published in the peer-reviewed journal Diabetes, Obesity and Metabolism .¹

GLP-1 medications can produce rapid weight loss,2 but lean mass can account for 30% or more of the weight lost.3,4 Lean mass is critical for overall health, as losing lean mass may contribute to reductions in resting metabolic rate5, impaired physical function and greater susceptibility to weight regain,6 as well as an increased risk for sarcopenia,7 frailty, and bone loss.6,8 While exercise and resistance training are known to be effective strategies for increasing fat loss while protecting lean mass,¹ much less is known about whether virtual care programs can improve body composition outcomes for people taking GLP-1 medications.

The study followed 245 adults with obesity who had started a GLP-1 for weight loss within the previous eight weeks.¹ Of those, 151 participated in Omada's GLP-1 Care Track and 94 received usual care, which could include medication alone or other, non-Omada lifestyle programs. More than a quarter (26%) of the usual care group reported using another lifestyle or wellness program during the study.¹

After 12 weeks, compared with the usual care group, Omada members on average:¹

  • Lost more weight (6.0% of starting body weight vs. 3.3%)
  • Reduced their body fat percentage by about twice as much (−3.3% vs. −1.6%)
  • Saw a larger increase in muscle mass percentage (+0.6% vs. +0.2%)
  • Reported greater improvements in well-being, physical functioning, and confidence in their ability to lose weight
  • Saw depression and anxiety symptoms drop by roughly 30%, significantly more than the usual care group

The GLP-1 Care Track provides clinical support between doctor visits. Members work with a care team that includes a dedicated health coach, GLP-1-specific peer support groups, digital tools for meal logging and behavior tracking, and AI-powered nutrition support.¹ The program also includes access to an exercise specialist who provides a personalized exercise plan developed by a physical therapist. Participants measured body composition at home using bioelectrical impedance scales.

"GLP-1 care is about more than how much weight you lose. It’s about the quality of the weight loss, as losing too much muscle can make it harder to keep the weight off long-term," said Thomas Tsang, MD, MPH, Chief Medical Officer at Omada Health. "Too many people are left to manage side effects, exercise, and nutrition on their own once GLP-1 treatment starts. This study suggests that clinical support between doctor visits can help people achieve greater weight loss and better body composition, and protect their muscle mass.”

This study was completed as part of the Omada Insights Lab ANSWERS (ANalyzing Success of WEight medication with Real-world evidence and Stats) Initiative, which examines and shares real-world data from Omada’s behavior change weight health programs.

Omada Health’s Clinical Research Scientist, Lisa A. Stanton, PhD, will present "Improving GLP-1 Weight Loss Quality with a Virtual Lifestyle Companion Program " on Tuesday, October 20, 2026, at 3:20 PM ET during the Anti-Obesity Drugs & Emerging Therapies session at WOC 2026, held October 19-21.

Omada Health

Omada Health (Nasdaq: OMDA) is reverse engineering the way healthcare is delivered in America, putting the space between doctor visits–where health is won or lost–at the center of care. Today's healthcare system poorly serves chronic conditions that require ongoing support outside of the exam room, like obesity, diabetes, hypertension, cholesterol, and musculoskeletal conditions. Omada’s virtual-first model combines human-led care teams, connected devices, and AI-enabled technology to deliver personalized care at scale, including support for GLP-1 therapy. Omada has served more than two million members since launch across 2,000+ employers, health plans, pharmacy benefit managers, and health systems. Learn more at omadahealth.com .

Media Contact

Rose Ramseth
[email protected]

  1. 1Stanton LA, Naqvi JB, Devaraj SM, et al. Quality Plus Quantity: Evaluation of a Virtual GLP-1 Programme With Physical Activity Support to Promote Healthy Body Composition Change During GLP-1 Weight Loss. Diabetes Obes Metab. 2026:1-12. doi:10.1111/dom.71152.
  2. 2Wilding JPH, Batterham RL, Calanna S, et al. Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med. 2021;384(11):989-1002. doi:10.1056/NEJMoa2032183
  3. 3Prado CM, Phillips SM, Gonzalez MC, Heymsfield SB. Muscle matters: the effects of medically induced weight loss on skeletal muscle. Lancet Diabetes Endocrinol. 2024;12(11):785-787. doi:10.1016/S2213-8587(24)00272-9
  4. 4Memel Z, Gold SL, Pearlman M, Muratore A, Martindale R. Impact of GLP-1 receptor agonist therapy in patients high risk for sarcopenia. Curr Nutr Rep. 2025;14(1):63. doi:10.1007/s13668-025-00649-w
  5. 5Hopkins M, Gibbons C, Blundell J. Fat-free mass and resting metabolic rate are determinants of energy intake: implications for a theory of appetite control. Philos Trans R Soc Lond B Biol Sci. 2023;378(1885):20220213. doi:10.1098/rstb.2022.0213
  6. 6Prado CMM, Heymsfield SB. Lean tissue imaging: a new era for nutritional assessment and intervention. JPEN J Parenter Enteral Nutr. 2014;38(8):940-953. doi:10.1177/0148607114550189
  7. 7Scheen AJ. GLP-1-derived therapies and sarcopenia: plea for a specific focus on at risk special populations. Diabetes Metab. 2025;52(1):101708. doi:10.1016/j.diabet.2025.101708
  8. 8Jensen SBK, Sørensen V, Sandsdal RM, et al. Bone health after exercise alone, GLP-1 receptor agonist treatment, or combination treatment: a secondary analysis of a randomized clinical trial. JAMA Netw Open. 2024;7(6):e2416775. doi:10.1001/jamanetworkopen.2024.16775

Related Content

See more

[Press Release
\

Omada Health to Announce Third Quarter 2026 Financial Results and Host Conference Call on November 5, 2026\


10/13/2026

Omada Health to Announce Third Quarter 2026 Financial Results and Host Conference Call on November 5, 2026](https://www.omadahealth.com/resource-center/omada-health-to-announce-third-quarter-2026-financial-results-and-host-conference-call-on-november-5-2026) [Press Release
\

Omada Health to Present Updated Long-Term Financial Targets at Inaugural Investor Day\


09/10/2026

Omada Health to Present Updated Long-Term Financial Targets at Inaugural Investor Day](https://www.omadahealth.com/resource-center/omada-health-to-present-updated-long-term-financial-targets-at-inaugural-investor-day) [Press Release
\

Independent Model Estimates Up To $11,142 in Gross Medical Cost Savings Per Member Over Five Years for Omada’s GLP-1 Program\


09/09/2026

Independent Model Estimates Up To $11,142 in Gross Medical Cost Savings Per Member Over Five Years for Omada’s GLP-1 Program](https://www.omadahealth.com/resource-center/independent-model-estimates-up-to-11142-in-gross-medical-cost-savings-per-member-over-five-years-for-omadas-glp-1-program)

See more

Become an Omada Insider

Sign Up

Footer Logo

© 2025 Omada Health Inc. All Rights Reserved.

Omada Health, Inc. works in partnership with Physera Physical Therapy Group, PC and other contracted partners to be your Omada care team and deliver certain clinical services as part of the Omada programs.

footer-legit

ADA State of Diabetes 2026 Partner Bull 1 Bear 0 Other

ADA State of Diabetes 2026 Partner

October 19-22, 2025 • Las Vegas, NV

Omada is proud to sponsor the American Diabetes Association® (ADA) State of Diabetes 2026 annual event in Chicago. This event brings employers, health plan leaders, and local advocates together for important conversations about diabetes, including how it affects people and workplaces, and practical ways to improve health and lower costs.

Kevin Masci, Pharm D , Senior Director of Clinical Affairs at Omada, will join a team of expert panelists to discuss this year's theme, "From Diabetes & Obesity Guidelines to Outcomes: Translating Evidence into Real-World Practice." The panel will explore how employers, payers, and community leaders can put the ADA's Standards of Care to work in ways that lead to measurable health improvements and cost savings.

ADA Logo

What we're looking forward to:

  • The latest in diabetes care and exploring resources that support healthier lives and access to care
  • Practical tools for turning guidelines into benefits, care pathways, and workplace policies
  • The chance to connect with employers, health plans and payers, and industry leaders working to improve diabetes outcomes

Register Now

Related Content

See more

[Webinars & Events
\

Beyond the Coverage Question: A New Playbook for Cardiometabolic Care\


10/05/2026

Beyond the Coverage Question: A New Playbook for Cardiometabolic Care](https://www.omadahealth.com/resource-center/beyond-the-coverage-question-a-new-playbook-for-cardiometabolic-care) [Webinars & Events
\

Beyond Point Solutions: Multi-Condition Support for Total Cost of Care\


09/10/2026

Beyond Point Solutions: Multi-Condition Support for Total Cost of Care](https://www.omadahealth.com/resource-center/beyond-point-solutions-multi-condition-support-for-total-cost-of-care) [Webinars & Events
\

The Story Between Visits: A New Lens on Cardiometabolic Care\


06/03/2026

The Story Between Visits: A New Lens on Cardiometabolic Care](https://www.omadahealth.com/resource-center/the-story-between-visits-a-new-lens-on-cardiometabolic-care)

See more

Become an Omada Insider

Sign Up

Footer Logo

© 2025 Omada Health Inc. All Rights Reserved.

Omada Health, Inc. works in partnership with Physera Physical Therapy Group, PC and other contracted partners to be your Omada care team and deliver certain clinical services as part of the Omada programs.

footer-legit

Prompts

Omada Health, Inc. (ticker OMDA), listed in United States.

ETFs Holding Omada Health, Inc.

ETF Weight in ETF Shares Market value As of
AFSM 0.07% 7,289 $ 105.618K Nov 16, 2026
FESM 0.05% 126,739 $ 2.782M Jun 30, 2026
FSEV 0.04% 128 $ 2,809.60 Jun 30, 2026
RESM 0.03% 49 $ 1,075.55 Jun 30, 2026
AVSC 0.01% 26,599 $ 385.42K Nov 16, 2026
MSSM 0.01% 2,510 $ 61.621K Aug 31, 2026
DFUS 0.00% 30,350 $ 446.145K Nov 12, 2026
DCOR 0.00% 32,619 $ 479.499K Nov 12, 2026
DFAC 0.00% 60,221 $ 885.249K Nov 12, 2026
DFAS 0.00% 5,279 $ 77.601K Nov 12, 2026
DFAU 0.00% 1,553 $ 22.829K Nov 12, 2026